Jeffrey R Chabot
Overview
Explore the profile of Jeffrey R Chabot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kapitanov G, Chabot J, Narula J, Roy M, Neubert H, Palandra J, et al.
Front Bioinform
. 2022 Oct;
1:731340.
PMID: 36303796
Quantitative modeling is increasingly utilized in the drug discovery and development process, from the initial stages of target selection, through clinical studies. The modeling can provide guidance on three major...
2.
Fung E, Kang L, Sapashnik D, Benard S, Sievers A, Liu Y, et al.
Sci Rep
. 2021 Apr;
11(1):8921.
PMID: 33903632
GDF15 is a distant TGF-β family member that induces anorexia and weight loss. Due to its function, GDF15 has attracted attention as a potential therapeutic for the treatment of obesity...
3.
Londregan A, Wei L, Xiao J, Lintner N, Petersen D, Dullea R, et al.
J Med Chem
. 2018 Jun;
61(13):5704-5718.
PMID: 29878763
The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound (1) were improved...
4.
Farrokhi V, Chabot J, Neubert H, Yang Z
Sci Rep
. 2018 May;
8(1):7781.
PMID: 29773891
Osteopontin is a secreted glycophosphoprotein that is highly implicated in many physiological and pathological processes such as biomineralization, cell-mediated immunity, inflammation, fibrosis, cell survival, tumorigenesis and metastasis. Antibodies against osteopontin...
5.
Weng Y, Ishino T, Sievers A, Talukdar S, Chabot J, Tam A, et al.
Sci Rep
. 2018 Mar;
8(1):4241.
PMID: 29523796
Pharmacological administration of FGF21 analogues has shown robust body weight reduction and lipid profile improvement in both dysmetabolic animal models and metabolic disease patients. Here we report the design, optimization,...
6.
McClure K, Piotrowski D, Petersen D, Wei L, Xiao J, Londregan A, et al.
Angew Chem Int Ed Engl
. 2017 Oct;
56(51):16218-16222.
PMID: 29073340
Targeting of the human ribosome is an unprecedented therapeutic modality with a genome-wide selectivity challenge. A liver-targeted drug candidate is described that inhibits ribosomal synthesis of PCSK9, a lipid regulator...
7.
Kim A, Somayaji V, Dong J, Rolph T, Weng Y, Chabot J, et al.
Diabetes Obes Metab
. 2017 Jun;
19(12):1762-1772.
PMID: 28573777
Aims: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analogue, in obese people with hypertriglyceridaemia on atorvastatin, with or without type...
8.
Dong J, Gosset J, Fahmi O, Lin Z, Chabot J, Terra S, et al.
Drug Metab Dispos
. 2017 Mar;
45(5):501-511.
PMID: 28254951
The propensity for CYP3A4 induction by 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2)-yl)acetamide (PF-06282999), an irreversible inactivator of myeloperoxidase, was examined in the present study. Studies using human hepatocytes revealed moderate increases in CYP3A4 mRNA and...
9.
Wang M, Kussrow A, Fernandez Ocana M, Chabot J, Lepsy C, Bornhop D, et al.
Br J Pharmacol
. 2016 Oct;
174(1):70-81.
PMID: 27760281
Background And Purpose: A monoclonal antibody (PF-00547659) against mucosal addressin cell adhesion molecule (MAdCAM), expressed as both soluble (sMAdCAM) and trans-membrane (mMAdCAM) target forms, showed over 30-fold difference in antibody-target...
10.
Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, et al.
Cell Metab
. 2016 Mar;
23(3):427-40.
PMID: 26959184
FGF21 plays a central role in energy, lipid, and glucose homeostasis. To characterize the pharmacologic effects of FGF21, we administered a long-acting FGF21 analog, PF-05231023, to obese cynomolgus monkeys. PF-05231023...